Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation
Tóm tắt
Osteoarthritis (OA) affects a large segment of the aging population and is a major cause of pain and disability. At present, there is no specific treatment available to prevent or retard the cartilage destruction that occurs in OA. Recently, glucosamine sulfate has received attention as a putative agent that may retard cartilage degradation in OA. The precise mechanism of action of glucosamine is not known. We investigated the effect of glucosamine in an in vitro model of cartilage collagen degradation in which collagen degradation induced by activated chondrocytes is mediated by lipid peroxidation reaction. Lipid peroxidation in chondrocytes was measured by conjugated diene formation. Protein oxidation and aldehydic adduct formation were studied by immunoblot assays. Antioxidant effect of glucosamine was also tested on malondialdehyde (thiobarbituric acid-reactive substances [TBARS]) formation on purified lipoprotein oxidation for comparison. Glucosamine sulfate and glucosamine hydrochloride in millimolar (0.1 to 50) concentrations specifically and significantly inhibited collagen degradation induced by calcium ionophore-activated chondrocytes. Glucosamine hydrochloride did not inhibit lipid peroxidation reaction in either activated chondrocytes or in copper-induced oxidation of purified lipoproteins as measured by conjugated diene formation. Glucosamine hydrochloride, in a dose-dependent manner, inhibited malondialdehyde (TBARS) formation by oxidized lipoproteins. Moreover, we show that glucosamine hydrochloride prevents lipoprotein protein oxidation and inhibits malondialdehyde adduct formation in chondrocyte cell matrix, suggesting that it inhibits advanced lipoxidation reactions. Together, the data suggest that the mechanism of decreasing collagen degradation in this in vitro model system by glucosamine may be mediated by the inhibition of advanced lipoxidation reaction, preventing the oxidation and loss of collagen matrix from labeled chondrocyte matrix. Further studies are needed to relate these in vitro findings to the retardation of cartilage degradation reported in OA trials investigating glucosamine.
Tài liệu tham khảo
Hamerman D: The biology of osteoarthritis. N Engl J Med. 1989, 320: 1322-1330.
Centers for Disease Control and Prevention (CDC): Update: direct and indirect costs of arthritis and other rheumatic conditions – United States, 1997. MMWR Morb Mortal Wkly Rep. 2004, 53: 388-389.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C: Long-term effect of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001, 357: 251-256. 10.1016/S0140-6736(00)03610-2.
Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002, 162: 2113-2123. 10.1001/archinte.162.18.2113.
Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY: Gluocosamine sulfate reduces osteoarthitis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause. 2004, 11: 138-143. 10.1097/01.GME.0000087983.28957.5D.
Altman RD, Abramson S, Bruyere O, Clegg D, Herrero-Beaumont G, Maheu E, Moskowitz R, Pavelka K, Reginster JY: Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage. 2006, 14: 963-966. 10.1016/j.joca.2006.06.010.
Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, et al: Glucosamine, chondroitin sulfate, and two in combination for painful knee osteoarthritis. N Engl J Med. 2006, 354: 795-808. 10.1056/NEJMoa052771.
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, Paulino J, Marenco JL, Porto A, Laffon A, et al: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007, 56: 555-567. 10.1002/art.22371.
Shikhman AR, Kuhn K, Alaaeddine N, Lotz M: N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol. 2001, 166: 5155-5160.
Meininger CJ, Kelly KA, Li H, Haynes TE, Wu G: Glucosamine inhibit inducible nitric oxide synthesis. Biochem Biophys Res Commun. 2000, 279: 234-239. 10.1006/bbrc.2000.3912.
Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M, Vignon E: Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 2000, 8: 207-212. 10.1053/joca.1999.0291.
Ilic MZ, Martinac B, Handley CJ: Effect of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage. Osteoarthritis Cartilage. 2003, 11: 613-622. 10.1016/S1063-4584(03)00092-X.
Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW: Glucosamine HCL reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage. 2000, 8: 258-265. 10.1053/joca.1999.0299.
Bassleer C, Rovati L, Franchimont P: Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage. 1998, 6: 427-434. 10.1053/joca.1998.0146.
Dodge GR, Jimenez SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage. 2003, 11: 424-432. 10.1016/S1063-4584(03)00052-9.
Sandy JD, Gamett D, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J. 1988, 335: 59-66.
Sandy JD, Thompson V, Verscharen C, Gamett D: Chondrocyte-mediated catabolism of aggrecan: evidence for a glycosylphosphatidylinositol-linked protein in the aggrecanase response to interleukin-1 or retinoic acid. Arch Biochem Biophys. 1999, 367: 258-264. 10.1006/abbi.1999.1234.
Gouze JN, Bianchi A, Bécuwe P, Dauça M, Netter P, Magdalou J, Terlain B, Bordji K: Glucosamine modulates IL-1 induced activation of rat chondrocytes at receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett. 2002, 510: 166-170. 10.1016/S0014-5793(01)03255-0.
Largo R, Alvarez-Soria MA, Díez-Ortego I, Calvo E, Sánchez-Pernaute O, Egido J, Herrero-Beaumont G: Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003, 11: 290-298. 10.1016/S1063-4584(03)00028-1.
Lippiello L, Woodward J, Karpman R, Hammad TA: In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res. 2000, 381: 229-240. 10.1097/00003086-200012000-00027.
Shikhman AR, Amiel D, D'Lima D, Hwang SB, Hu C, Xu A, Hashimoto S, Kobayashi K, Sasho T, Lotz MK: Chondroprotective activity if N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis. 2005, 64: 89-94. 10.1136/ard.2003.019406.
Tamai Y, Miyatake K, Okamoto Y, Takamori Y, Sakamoto H, Minami S: Enhanced healing of cartilaginous injuries by glucosamine hydrochloride. Carbohydrate Polymers. 2002, 48: 369-378. 10.1016/S0144-8617(01)00281-8.
Tiraloche G, Girard C, Chouinard L, Sampalis J, Moquin L, Ionescu M, Reiner A, Poole AR, Laverty S: Effect of oral glucosamine on cartilage degradation in rabbit model of osteoarthritis. Arthritis Rheum. 2005, 52: 1118-1128. 10.1002/art.20951.
Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lakomy R, Qian S, Lu L, Robbins PD, Trucco M, et al: Immunosuppressive effects of glucosamine. J Biol Chem. 2002, 277: 39343-39349. 10.1074/jbc.M204924200.
Quastel JH, Cantero A: Inhibition of tumour growth by D-glucosamine. Nature. 1953, 171: 252-254. 10.1038/171252a0.
Tiku ML, Shah R, Allison GT: Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J Biol Chem. 2000, 275: 20069-20076. 10.1074/jbc.M907604199.
Rifici VA, Khachadurian AK: Dietary supplementation with vitamin C and E inhibit in vitro oxidation of lipoproteins. J Am Coll Nutr. 1993, 12: 631-637.
Lavy A, Brook GJ, Dankner G, Ben Amotz A, Aviram M: Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 1991, 40: 794-799. 10.1016/0026-0495(91)90005-H.
Laemmli UK: Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.
Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996, 98: 800-814.
Shacter EY, Williams JA, Stadtman ER: Determination of carbonyl groups in oxidized proteins. Free Radicals: A Practical Approach. Edited by: Punchard NA, Kelly FJ. 1996, Oxford University Press, New York: IRL Press, 159-170.
Gutteridge JM: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem. 1995, 41: 1819-1828.
Berlett BS, Stadtman ER: Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997, 272: 20313-20316. 10.1074/jbc.272.33.20313.
Tamarit J, Cabiscol E, Ros J: Identification of major oxidatively damaged proteins in Escherichia coli cells exposed to oxidative stress. J Biol Chem. 1998, 273: 3027-3032. 10.1074/jbc.273.5.3027.
Tiku ML, Allison GT, Naik K, Karry SK: Malondialdehyde oxidation of cartilage collagen by chondrocytes. Osteoarthritis Cartilage. 2003, 11: 159-166. 10.1016/S1063-4584(02)00348-5.
Shah R, Raska K, Tiku ML: The presence of molecular markers of in vivo lipid peroxidation in osteoarthritic cartilage: a pathogenic role in osteoarthritis. Arthritis Rheum. 2005, 52: 2799-2807. 10.1002/art.21239.
Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M: Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum. 2006, 54: 271-281. 10.1002/art.21559.
Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem. 2000, 275: 21177-21184. 10.1074/jbc.M003263200.
Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW: Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003, 278: 42012-42019. 10.1074/jbc.M304292200.
Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic rat. Kidney Int. 2002, 61: 939-950. 10.1046/j.1523-1755.2002.00207.x.
Requena JR, Vidal P, Cabezas-Cerrato J: Aminoguanidine inhibits the modification of proteins by lipid peroxidation derived aldehyde: a possible anti-atherogenic agent. Diabetes Res. 1992, 20: 43-49.
Picard S, Parthasarathy S, Fruebis J, Witztum JL: Aminoguanidine inhibits oxidative modification of low-density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA. 1992, 89: 6876-6880. 10.1073/pnas.89.15.6876.
Voziyan PA, Metz TO, Baynes JW, Hudson BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediated of carbohydrates and lipid degradation. J Biol Chem. 2002, 277: 3397-3403. 10.1074/jbc.M109935200.
Uchiyama A, Ohishi T, Takahashi M, Kushida K, Inoue T, Fujie M, Horiuchi K: Fluorophores from aging human cartilage. J Biochem (Tokyo). 1991, 110: 714-718.
Hormel SE, Eyre DR: Collagen in the ageing human intervertebral disc: an increase in covalently bound fluorophores and chromophores. Biochim Biophys Acta. 1991, 1078: 243-250.
Pokharna HK, Monnier V, Boja B, Moskowitz RW: Lysyl oxidase and Maillard reaction-mediated crosslinks in aging and osteoarthritic rabbit cartilage. J Orthop Res. 1995, 13: 13-21. 10.1002/jor.1100130105.
Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999, 48: 1-9. 10.2337/diabetes.48.1.1.
Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB- a novel inhibitor of advanced glycation. Diabetes. 1995, 46: 895-899. 10.2337/diabetes.46.5.895.
Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M: Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology. 1997, 138: 1886-1892. 10.1210/en.138.5.1886.
Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986, 232: 1629-1632. 10.1126/science.3487117.
Lo TW, Selwood T, Thornalley PJ: The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol. 1994, 48: 1865-1870. 10.1016/0006-2952(94)90584-3.
Lubec B, Aufricht C, Amann G, Kitzmüller E, Höger H: Arginine reduces kidney collagen accumulation, cross-linking, lipid peroxidation, glycoxidation, kidney weight and albuminuria in diabetic KK mouse. Nephron. 1997, 75: 213-218.
Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N: Reaction of metformin with dicaronyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol. 1999, 58: 1765-1773. 10.1016/S0006-2952(99)00263-4.
Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005, 13: 1041-1049. 10.1016/j.joca.2005.07.009.